Advertisement

Applied Health Economics and Health Policy

, Volume 16, Issue 3, pp 357–366 | Cite as

Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation

  • William J. Valentine
  • Kate Van Brunt
  • Kristina S. Boye
  • Richard F. Pollock
Original Research Article

Abstract

Objective

The aim of the present study was to evaluate the cost effectiveness of rapid-acting analog insulin relative to regular human insulin in adults with type 1 diabetes mellitus in Germany.

Methods

The PRIME Diabetes Model, a patient-level, discrete event simulation model, was used to project long-term clinical and cost outcomes for patients with type 1 diabetes from the perspective of a German healthcare payer. Simulated patients had a mean age of 21.5 years, duration of diabetes of 8.6 years, and baseline glycosylated hemoglobin of 7.39%. Regular human insulin and rapid-acting analog insulin regimens reduced glycosylated hemoglobin by 0.312 and 0.402%, respectively. Compared with human insulin, hypoglycemia rate ratios with rapid-acting analog insulin were 0.51 (non-severe nocturnal) and 0.80 (severe). No differences in non-severe diurnal hypoglycemia were modeled. Discount rates of 3% were applied to future costs and clinical benefits accrued over the 50-year time horizon.

Results

In the base-case analysis, rapid-acting analog insulin was associated with an improvement in quality-adjusted life expectancy of 1.01 quality-adjusted life-years per patient (12.54 vs. 11.53 quality-adjusted life-years). Rapid-acting analog insulin was also associated with an increase in direct costs of €4490, resulting in an incremental cost-effectiveness ratio of €4427 per quality-adjusted life-year gained vs. human insulin. Sensitivity analyses showed that the base case was driven predominantly by differences in hypoglycemia; abolishing these differences reduced incremental quality-adjusted life expectancy to 0.07 quality-adjusted life-years, yielding an incremental cost-effectiveness ratio of €74,622 per quality-adjusted life-year gained.

Conclusions

Rapid-acting analog insulin is associated with beneficial outcomes in patients with type 1 diabetes and is likely to be considered cost effective in the German setting vs. regular human insulin.

Notes

Author contributions

KSB and KVB devised the research question. All authors were involved in devising the literature search strategy. WJV and RFP then ran the literature searches, screened the retrieved literature, and extracted the data used in the final analyses. All authors were subsequently involved in scrutinizing and, where necessary, revising the simulation plans for the final analyses. RFP ran the analyses in the PRIME Diabetes Model, which were cross-checked with the original data sources by WJV. RFP and WJV wrote the first draft of the manuscript, with KSB and KVB making substantive revisions prior to submission.

Compliance with Ethical Standards

Funding

The study was funded by Eli Lilly and Company.

Conflict of interest

Richard F. Pollock and William J. Valentine are full-time employees of Ossian Health Economics and Communications GmbH, which received consultancy fees from Eli Lilly and Company to conduct the analysis and for the preparation of the manuscript. Kristina S. Boye and Kate Van Brunt are full-time employees of Eli Lilly and Company, which manufactures the rapid-acting insulin Humalog (Insulin lispro) and other antidiabetic agents.

Ethical approval

No patient-level data were used as part of the present study. As such, ethics approval and patient consent were neither required nor sought.

Supplementary material

40258_2018_379_MOESM1_ESM.docx (746 kb)
Supplementary material 1 (DOCX 746 kb)

References

  1. 1.
    IDF Atlas, Version 6. 2015. https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed 22 Dec 2015.
  2. 2.
    Bächle C, Icks A, Straßburger K, Flechtner-Mors M, Hungele A, Beyer P, Placzek K, Hermann U, Schumacher A, Freff M, Stahl-Pehe A, Holl RW. Rosenbauer J; DPV Initiative and the German BMBF Competence Network Diabetes Mellitus. Direct diabetes-related costs in young patients with early-onset, long-lasting type 1 diabetes. PLoS One. 2013;8(8):e70567.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Köster I, Hauner H, von Ferber L. Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study. Dtsch Med Wochenschr. 2006;131(15):804–10.CrossRefPubMedGoogle Scholar
  4. 4.
    von Ferber L, Köster I, Hauner H. Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the German CoDiM Study. Exp Clin Endocrinol Diabetes. 2007;115(2):97–104.CrossRefGoogle Scholar
  5. 5.
    Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Rosenbauer J, Stahl A. Häufigkeit des Diabetes mellitus im Kindes: und Jugendalter in Deutschland. Der Diabetologe. 2010;10(6):177–89.CrossRefGoogle Scholar
  7. 7.
    Grunberger G. Insulin analogs: are they worth it? Yes! Diabetes Care. 2014;37(6):1767–70.CrossRefPubMedGoogle Scholar
  8. 8.
    IQWiG Reports. Commission No. A05-02. Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1. 2007. www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf. Accessed 16 Feb 2018.
  9. 9.
    Holden SE, Currie CJ. Do the benefits of analog insulins justify their costs? Diabetes Manage. 2012;2(3):173–5.CrossRefGoogle Scholar
  10. 10.
    Holden SE, Poole CD, Morgan CL, Currie CJ. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open. 2011;1(2):e000258.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl. 1):S5–26.CrossRefPubMedGoogle Scholar
  12. 12.
    Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM. Holman RR; UKPDS Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747–59.CrossRefPubMedGoogle Scholar
  13. 13.
    Zgibor JC, Piatt GA, Ruppert K, Orchard TJ, Roberts MS. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care. 2006;29(8):1860–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Farmer AJ, Stevens R, Hirst J, Lung T, Oke J, Clarke P, Glasziou P, Neil A, Dunger D, Colhoun HM, Pugh C, Wong G, Perera R, Shine B. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment: systematic review and modelling of progression and cost-effectiveness. Health Technol Assess. 2014;18(14):1–128.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Valentine W, Pollock RF, Saunders R, Bae J, Norrbacka K, Curtis B, Boye K. Predicting complications and long-term outcomes in type 1 diabetes: the PRIME Diabetes Model. Paper presented at the European Association for the Study of Diabetes Annual Meeting, Stockholm, 15–18 September 2015.Google Scholar
  16. 16.
    Valentine WJ, Pollock RF, Saunders R, Bae J, Norrbacka K, Boye K. The PRIME Diabetes Model: novel methods for estimating long-term clinical and cost outcomes in type 1 diabetes mellitus. Value Health. 2017;20(7):985–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Boye KS, Lage ME, Treglia M, Lage MJ, Valentine W, Pollock RF, Saunders R. Verification and validation of health economic models for diabetes. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 18th Annual European Congress, Milan, 7–11 November 2015.Google Scholar
  18. 18.
    DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002;325(7367):746.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, Holl RW. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007;30(10):2523–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Hammes HP, Kerner W, Hofer S, Kordonouri O, Raile K. Holl RW; DPV-Wiss Study Group. Diabetic retinopathy in type 1 diabetes: a contemporary analysis of 8784 patients. Diabetologia. 2011;54(8):1977–84.CrossRefPubMedGoogle Scholar
  21. 21.
    Brunetti P, Muggeo M, Cattin L, Arcangeli A, Pozzilli P, Provenzano V, Francesconi A, Calatola P, Santeusanio F. Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine. Nutr Metab Cardiovasc Dis. 2010;20(7):519–26.CrossRefPubMedGoogle Scholar
  22. 22.
    World Health Organization. Global Health Observatory (GHO) data. Life tables. 2015. http://www.who.int/gho/mortality_burden_disease/life_tables/life_tables/en/. Accessed 16 Feb 2018.
  23. 23.
    Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Res Clin Pract. 2006;71(2):131–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Singh S, Ahmad F, Lal A, Yu C, Bai Y, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009;180(4):385–97.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Karges B, Rosenbauer J, Kapellen T, Wagner VM, Schober E, et al. Hemoglobin A1c levels and risk of severe hypoglycemia in children and young adults with type 1 diabetes from Germany and Austria: a trend analysis in a cohort of 37,539 patients between 1995 and 2012. PLoS Med. 2014;11(10):e1001742.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kulzer B, Seitz L, Kern W. Real-world patient-reported rates of non-severe hypoglycaemic events in Germany. Exp Clin Endocrinol Diabetes. 2014;122(3):167–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes. 2013;5(4):482–91.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Sanches ACC, Correr CJ, Venson R, Goncalves PR, Garcia MM, Piantavini MS, Pontarolo R. Insulin analogues versus human insulin in type 1 diabetes: direct and indirect meta-analyses of efficacy and safety. Braz J Pharm Sci. 2013;49(3):501–9.CrossRefGoogle Scholar
  29. 29.
    Blanco CG, Ballesteros AC, Saladich IG, Pla RC. Glycemic control and pregnancy outcomes in women with type 1 diabetes mellitus using lispro versus regular insulin: a systematic review and meta-analysis. Diabetes Technol Ther. 2011;13(9):907–11.CrossRefGoogle Scholar
  30. 30.
    Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol. 2010;47(Suppl. 1):77–81.CrossRefPubMedGoogle Scholar
  31. 31.
    Ashwell S, Amiel S, Bilous R. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med. 2006;23(3):285–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Rote Liste® Service GmbH. Die Rote Liste. 2018. http://online.rote-liste.de/. Accessed 16 Feb 2018.
  33. 33.
    Laubner K, Molz K, Kerner W, et al. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database. Diabetes Metab Res Rev. 2014;30(5):395–404.CrossRefPubMedGoogle Scholar
  34. 34.
    Smith-Palmer J, Bae JP, Boye KS, Norrbacka K, Hunt B, Valentine WJ. Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes. Clinicoecon Outcomes Res. 2016;8:559–71.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Reimer A, Schmitt A, Ehrmann D, Hermanns N, Kulzer B, Haak T. Geringere Lebensqualität und höhere gesundheitsökonomische Kosten bei Menschen mit Diabetes und erhöhter Depressivität. Diabetologie und Stoffwechsel. 2015;10:P132.CrossRefGoogle Scholar
  36. 36.
    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden 4.2. 2015. https://www.iqwig.de/download/IQWiG_General_Methods_Version_%204-2.pdf. Accessed 16 Feb 2018.
  37. 37.
    Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, Schall I, Hebborn A, Pugner K, Fehervary A, Brixner D, Siebert U. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015;4(5):485–504.CrossRefPubMedGoogle Scholar
  38. 38.
    Wirth D, Dass R, Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res. 2017;17(1):182.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Heinzel A, Stock S, Langen KJ, Müller D. Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas. J Nucl Med. 2012;53(4):552–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Lux MP, Hartmann M, Jackisch C, Raab G, Schneeweiss A, Possinger K, Oyee J, Harbeck N. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. Breast Cancer Res Treat. 2009;117(2):305–17.CrossRefPubMedGoogle Scholar
  41. 41.
    Lauridsen JT, Lønborg J, Gundgaard J, Jensen HH. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Qual Life Res. 2014;23(9):2645–50.CrossRefPubMedGoogle Scholar
  42. 42.
    Canadian Agency for Drugs and Technologies in Health. Second- and third-line pharmacotherapy for type 2 diabetes: update. CADTH optimal use reports. Ottawa, ON: CADTH; 2013.Google Scholar
  43. 43.
    Consensus American Diabetes Association. P. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27(9):2262–5.CrossRefGoogle Scholar
  44. 44.
    Control Diabetes, Trial Complications. (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016;39(8):1378–83.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Ossian Health Economics and Communications GmbHBaselSwitzerland
  2. 2.Eli Lilly and CompanyWindleshamUK
  3. 3.Eli Lilly and CompanyIndianapolisUSA

Personalised recommendations